CASSAVA SCIENCES INC. - COMMON STOCK

Cassava Sciences Reports Third Quarter 2021 Financial Results

10 Nov 2021 06:00:01 By Nasdaq GlobeNewswire

Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences’ Lead Drug Candidate

04 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer’s Disease

06 Oct 2021 05:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-label Study Evaluating Simufilam in Alzheimer’s Disease

22 Sep 2021 05:30:00 By Nasdaq GlobeNewswire

Cassava Sciences to Present at H.C. Wainwright’s 23rd Annual Global Investment Conference

09 Sep 2021 05:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Releases a Public Statement Regarding Recent Allegations

03 Sep 2021 04:00:00 By Nasdaq GlobeNewswire

Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer’s Patients

27 Aug 2021 08:31:59 By Nasdaq GlobeNewswire

Cassava Sciences Responds to Allegations

25 Aug 2021 03:00:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

24 Aug 2021 05:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports Second Quarter 2021 Financial Results

03 Aug 2021 05:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Conference Call for Second Quarter Financial Results

02 Aug 2021 16:54:18 By Nasdaq GlobeNewswire

Cassava Sciences Announces Positive Biomarker Data with Simufilam in Alzheimer’s Disease

29 Jul 2021 06:53:35 By Nasdaq GlobeNewswire

Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer’s Disease

29 Jul 2021 06:53:30 By Nasdaq GlobeNewswire

Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam

26 Jul 2021 05:30:00 By Nasdaq GlobeNewswire

Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference

21 Jul 2021 05:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer’s Disease

21 Jun 2021 13:10:00 By Nasdaq GlobeNewswire

Cassava Sciences Provides Mid-Year Corporate Update, Clinical Development Progress and Announces Guidance on Clinical Data Release

21 Jun 2021 05:30:00 By Nasdaq GlobeNewswire

Cassava Sciences to Present at the Raymond James 2021 Human Health Innovation Conference

17 Jun 2021 13:01:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors

14 Jun 2021 05:30:00 By Nasdaq GlobeNewswire

Cassava Sciences to Participate in Q&A Panel Discussion on Alzheimer’s Disease

24 May 2021 05:30:00 By Nasdaq GlobeNewswire